Patents by Inventor Michael L. Shuler
Michael L. Shuler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200070165Abstract: A device is disclosed that comprises a base having first and second reservoirs, each having an inlet and an outlet, and a channel layer comprising an inlet channel in fluid communication with the inlets of the reservoirs, one or more outlet channels in fluid communication with the outlets of the reservoirs, and a channel network comprising at least one channel extending therebetween. In a forward tilted position, a first fluid circuit is formed from the outlet of the first reservoir, through the one or more outlet channels, through the channel network, through the inlet channel, to the both the inlet and outlet of the second reservoir. In a reverse tilted position a second fluid circuit is formed from the outlet of the second reservoir, through the one or more outlet channels, through the channel network, through the inlet channel, to both the inlet and outlet of the first reservoir. Methods of using the device are also disclosed.Type: ApplicationFiled: June 14, 2019Publication date: March 5, 2020Inventors: Michael L. SHULER, Ying WANG
-
Patent number: 8748180Abstract: A microfluidic device for culturing cells, termed a microscale cell culture analog (?CCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.Type: GrantFiled: July 29, 2010Date of Patent: June 10, 2014Assignee: Cornell UniversityInventors: Michael L. Shuler, Jong Hwan Sung
-
Publication number: 20120135452Abstract: A microfluidic device for culturing cells, termed a microscale cell culture analog (?CCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.Type: ApplicationFiled: July 29, 2010Publication date: May 31, 2012Applicant: Cornell UniversityInventors: Michael L. Shuler, Jong Hwan Sung
-
Publication number: 20040057969Abstract: The present invention relates to a composition, which includes a hepatitis B surface antigen stabilized with a milk protein and/or a milk protein component. This composition can be used in an oral vaccine for treatment of hepatitis B. The present invention further relates to methods of immunizing a subject against hepatitis, methods of administrating the composition of the present invention, and methods of producing a stabilized hepatitis B surface antigen protein.Type: ApplicationFiled: September 20, 2002Publication date: March 25, 2004Inventors: Mark L. Smith, Michael L. Shuler
-
Patent number: 5942421Abstract: A single celled organism, vector, and method are provided for continuous production of excreted proteins in the absence of substantial host cell replication and without the necessity for the addition of antibiotics to control cell replication. The vector has (1) an inducible promoter capable of activating a gene for a protein to be produced under conditions that substantially inhibit host cell replication, and (2) a hybrid gene containing a signal sequence fused to a gene for the protein to be produced. Large quantities of the transformed single celled organisms containing the vector can be grown in the absence of inducing conditions, thereby reducing the problem of plasmid loss. Further, the protein is produced under conditions that substantially inhibit host cell replication, thereby allowing immobilization of the single celled organism by entrapment or attachment within or onto a solid support surface. The single celled organism can be immobilized after, before or simultaneously with induction.Type: GrantFiled: November 18, 1997Date of Patent: August 24, 1999Assignee: Cornell Research Foundation, Inc.Inventors: Michael L. Shuler, David B. Wilson
-
Patent number: 5747281Abstract: A single celled organism, vector, and method are provided for continuous production of excreted proteins in the absence of substantial host cell replication and without the necessity for the addition of antibiotics to control cell replication. The vector has (1) an inducible promoter capable of activating a gene for a protein to be produced under conditions that substantially inhibit host cell replication, and (2) a hybrid gene containing a signal sequence fused to a gene for the protein to be produced. Large quantities of the transformed single celled organisms containing the vector can be grown in the absence of inducing conditions, thereby reducing the problem of plasmid loss. Further, the protein is produced under conditions that substantially inhibit host cell replication, thereby allowing immobilization of the single celled organism by entrapment or attachment within or onto a solid support surface. The single celled organism can be immobilized after, before or simultaneously with induction.Type: GrantFiled: June 7, 1995Date of Patent: May 5, 1998Assignee: Cornell Research Foundation, Inc.Inventors: Michael L. Shuler, David B. Wilson
-
Patent number: 5728580Abstract: Non-carboxylated sulfated polyanions have been successfully used to rapidly obtain and maintain stable single-cell suspension of BTI-TN5B1-4 cells, a cell line which has a high intrinsic capacity for the expression of recombinant protein, but which clumps severely in suspension reducing its effectiveness as a host for foreign protein production with the baculovirus expression vector system. The three most effective polyanions for inducing a single-cell suspension were dextran sulfate, polyvinyl sulfate, and pentosan sulfate. The cost of dextran sulfate treatment is low compared to heparin treatment, which required a 20-fold higher lever to induce single-cell suspension. More importantly, dextran sulfate does not block vital infection at MOI.gtoreq.1 whereas heparin is known to seriously inhibit infection.Type: GrantFiled: February 20, 1996Date of Patent: March 17, 1998Assignee: Cornell Research Foundation, Inc.Inventors: Michael L. Shuler, Kennie U. Dee
-
Patent number: 5612188Abstract: The present invention relates to an in vitro system for physiological and metabolic evaluation of substances for use in living beings. The system includes one or more cell culture chambers, each containing cells in a culture medium and a gas-liquid exchange device for contacting the culture medium with oxygen-containing gas so that the culture medium absorbs that gas and desorbs carbon dioxide-containing gas. The conduit system conducts culture medium between the gas-liquid exchange device and the cell culture chambers. A circulation mechanism is used to circulate culture medium through the conduit system, the cell culture chambers, and the gas-liquid exchange device. In use, the substance to be evaluated is added to the culture medium of the system and circulated through the system. The cells in each of the cell culture chambers are then evaluated for effects resulting from the presence of the substance.Type: GrantFiled: February 10, 1994Date of Patent: March 18, 1997Assignee: Cornell Research Foundation, Inc.Inventors: Michael L. Shuler, John G. Babish, Lisa M. Sweeney, Brian E. Johnson
-
Patent number: 5244794Abstract: Root organ cultures of the monocot genus Allium were successfully grown in culture medium. In a preferred bioreactor system, the roots themselves can be grown and harvested as a source of various Allium flavors and/or the growing roots can be reacted with various nutrients to produce Allium flavor compounds independent of the root harvesting. The root cultures of the present invention produce quantities of onion and onion-like flavor compounds comparable to those found in onion bulbs.Flavor precursors arThis invention was made in part under NSF Grant No. 85-03183. The U.S. Government has certain rights to this invention.Type: GrantFiled: June 28, 1991Date of Patent: September 14, 1993Assignee: Cornell Research Foundation, Inc.Inventors: Christopher Prince, Michael L. Shuler
-
Patent number: 4940547Abstract: An immobilized liquid membrane is employed to allow use of a product-extracting solvent which is normally toxic toward a cell layer which produces the product in a membrane-moderated biological reaction.Type: GrantFiled: July 7, 1986Date of Patent: July 10, 1990Assignee: Cornell Research Foundation, Inc.Inventors: Toohyon Cho, Michael L. Shuler
-
Patent number: 4861483Abstract: An improved multilayer continuous biological membrane reactor and a process to eliminate diffusional limitations in membrane reactors in achieved by causing a convective flux of nutrient to move into and out of an immobilized biocatalyst cell layer. In a pressure cycled mode, by increasing and decreasing the pressure in the respective layers, the differential pressure between the gaseous layer and the nutrient layer is alternately changed from positive to negative. The intermittent change in pressure differential accelerates the transfer of nutrient from the nutrient layers to the biocatalyst cell layer, the transfer of product from the cell layer to the nutrient layer and the transfer of byproduct gas from the cell layer to the gaseous layer. Such intermittent cycling substantially eliminates mass transfer gradients in diffusion inhibited systems and greatly increases product yield and throughput in both inhibited and noninhibited systems.Type: GrantFiled: June 17, 1988Date of Patent: August 29, 1989Assignee: Cornell Research Foundation, Inc.Inventors: George S. Efthymiou, Michael L. Shuler